Wednesday, 26th April Asia-Pacific Vaccine and Immunotherapy Congress 2023

Honourable Dr. Steven Miles MP
Deputy Premier, Minister for State Development, Infrastructure, Local Government and Planning
Minister Assisting the Premier on Olympic and Paralympic Games Infrastructure
Queensland Government

• Immune Memory to COVID-19 - Rafi Ahmed
• High dimensionality dissection of the diseased human Immunome - Salvatore Albani
• Development and trials of antigen-specific immunotherapy in rheumatoid arthritis and type 1 diabetes - Ranjeny Thomas

• Factors impacting outcomes of CD19 CAR-T cell immunotherapy - Cameron Turtle
• Place-of-care CAR T cell therapy - Siok Tey
• Immunotherapy strategies for allogeneic stem cell transplant immune repair - Emily Blyth
• Off-the-shelf CAR T cell immunotherapy for glioblastoma - Paulo Martins
• Adoptive transfer of T_STEM-like CAR-T cells mediates improved persistence and tumor control - Joe Zhu
• Adoptive T cell Immunotherapy for SARS-CoV-2 - Corey Smith

• The function and specificity of T cells in asymptomatic SARS-CoV-2 infection - Antonio Bertoletti
• The immune infiltrate in breast cancer and relevance for prognosis and checkpoint inhibition - Sherene Loi
• Humanised mouse models for translation of immunotherapies - Kristen Radford
• Using 3D genomics to connect genetic risk to the genes that cause loss of tolerance, and developing immunotherapies to prevent T1D - Simon Barry
• Prognostic implications of anti-tumoural T-cell immunity targeting abundant B-cell receptor neoantigens in IGHV-mutated chronic lymphocytic leukemia - Muhammed B. Sabdia

• Allogeneic EBV T-Cell Therapies: Ushering in the Next Wave of Innovation in Autoimmune Diseases and Cancer - Jakob Dupont
• Novel methods to improve efficacy of CAR T cell therapies in solid cancers - Rebecca Lim
• LGR5-targeting CAR-T cells – The road to the Clinic - Shaun McColl
• Developing first in class gd1 CAR T cells for heme malignancies and solid tumours - Blake Aftab

Speakers include:

Cokey Nguyen, Global R&D Head, Atara Biotherapeutics, Thousand Oaks, CA, USA

Rebecca Lim, Chief Scientific Officer, Prescient Therapeutics, Melbourne

Shaun McColl, Vice President of Chemokine Platform Technology, Carina Biotech

Blake Aftab, Chief Scientific Officer, Adicet Bio

Fireside Chat - Challenges in delivering commercial cell therapy drug products
- Cokey Nguyen, Rebecca Lim, Blake Aftab, Sam Cobb and Goslik Schepers

• Can regulatory T cell manipulation prevent Cutaneous Squamous Cell Carcinoma? - Shoaib Anwaar
• Understanding the contribution of immature myeloid cells to early melanoma establishment - Xiaoyu Hou
• Influence of melanoma diagnosis on the circadian variation of lymphocytes - David C. Qian
• Cytokine-antibody complexes between IL-2 and S4B6 expand CD4/CD8 double-positive T cells in vivo. - Wei Yang Kong
• Superior efficacy of a Zika skin-patch NS1 DNA vaccine - Danushka K Wijesundara
• Development of a novel approach for the prevention and treatment of squamous cell carcinoma in organ transplant recipients - James W Wells
• Immunoinformatic prediction of SARS-CoV-2 T-cell epitopes and ELISPOT assays on the PBMC samples from Indonesian people as the first step for vaccine design - Marsia Gustiananda
• Spatial-Omics pipeline to aid personalization of precision medicine in metastatic recurrent Head & Neck Cancers - Xuehan Lu
• Poly(hydrophobic amino acids) as an adjuvant for subunit vaccines - Lantian Lu
• Overcoming Immune Checkpoint Inhibitor Resistance to Improve Melanoma Therapy - Sheena M Daignault
• Defining the principles of T cell-mediated melanoma rejection. - Sarah Jahfali
• Characterising the role of NKG7 in CD4⁺ and CD8⁺ T cells during blood-stage malaria - Teija Frame
• Understanding CD4⁺ T cell mediated immune regulation in malaria: Assessing the immunomodulatory potential of Ruxolitinib during controlled human malaria infection. - Luzia Bukali
• Contrasting roles of NKG7 and TGFβ during Leishmania donovani infection - Jinrui Na
• engineering human antigen-presenting cells for tolerogenic gene therapy in humanised mice - Clara Heider
• Nucleic acid reference materials for accurate measurements in gene therapy, pandemic preparedness and vaccine development - Anna Baoutina
• Intestinal Graft-versus-Host-Disease in a dish - Amir Shamshirian
• Immunotherapy in Canine Osteosarcoma - Abhilasha Dadhich
• Targeting Cancer Neoantigens: The Potential of Personalized Peptide-Based Vaccine for Advanced Solid Tumor Patients - Lantian Lu
• A surgically optimised intraoperative poly(I:C) releasing hydrogel prevents cancer recurrence - Francois X Rwandamuriye
• Towards development of novel peptide subunit vaccine for Tuberculosis   - Viet Tram Duong
• Ferroptosis-mitigating Glutathione peroxidase 4 (GPX4) is indispensable for the homeostasis and function of T_FH cells. - Naiqi Wang
• Non-invasive detection of dermal NAD+ using multiphoton imaging due to nicotinamide mononucleotide loaded microneedles as a possible treatment for aging-related diseases - Masood MA Ali
• Comparative analysis of Spike-specific memory T cell profiles and responses following COVID-19 mRNA vaccination or natural infection - Martin Daniel Qui
• Amphiphilic peptides in combination with polyglutamic acids -modified antigens as a self-adjuvating vaccine delivery systems - Jingyi FAN
• Proinflammatory impact of viral-specific CD8+ T cells infiltrating new-onset seropositive rheumatoid arthritis synovium - Hanno Nel
• Role of microneedle topography on vaccine coating - Yanling Yang
• A lymph node targeted molecular adjuvant and engineered subunit antigen vaccine promotes potent cellular and humoral immunity to Epstein-Barr Virus in HLA-expressing mice   - Vijayendra Dasari
• Flt3L and CD40L-expressing CAR T cell therapy drives activation of antitumour immunity to overcome tumour heterogeneity - Cheok Weng Chan
• Development of poly (hydrophobic amino acid)-based mannose receptor targeting delivery systems for vaccine against Group A streptococcus - JINGWEN WANG

New Developments in Cancer Immunotherapy

Moderator: Ms. Clare Blake (QIMR Berghofer)

Patient’s Perspective:

Clinicians’ Perspective:

Prof Ranjeny Thomas (Frazer Institute, UQ)
Dr. Siok Tey (QIMR Berghofer)
Dr. Emily Blythe (The Westmead Institute for Medical Research, Sydney)

Q&A Session